This activity is supported by an educational grant from Lilly.

Join Charlene Gamaldo, MD, Professor of Neurology at Johns Hopkins School of Medicine, in a discussion on translating the latest evidence from the SLEEP 2026 Annual Meeting into real-world obstructive sleep apnea (OSA) practice. This module explores strategies to move beyond CPAP monotherapy by leveraging disease endotypes and phenotypes to personalize care, integrating anti-obesity pharmacotherapy into sleep management pathways, and structuring therapy selection, sequencing, and long-term patient monitoring.

Session highlights

• Evaluate treatment triggers and CPAP alternatives: Identify when PAP monotherapy is insufficient or poorly tolerated and determine clinical criteria for escalating to alternative or multimodal options.
• Select and sequence non-PAP interventions: Apply physiological endotyping and clinical phenotypes to guide non-PAP modalities, including oral appliances, positional therapy, and surgical interventions.
• Integrate weight management into OSA care: Incorporate anti-obesity medications into comprehensive treatment plans, manage side effects, and establish coordinated shared-care pathways.
• Optimize long-term management and reassessment: Implement structured follow-up routines to track therapy persistence, address treatment tolerability, and strategically time repeat sleep testing during weight changes or therapy transitions.

Prefer to read? See our Key Clinical Summary Here.

Who Should Participate

This activity is intended for healthcare practitioners involved in the diagnosis, clinical evaluation, and longitudinal management of patients with obstructive sleep apnea (OSA).

Faculty

Professor Charlene Gamaldo MD, is a neurologist and sleep medicine specialist at Johns Hopkins University. She earned her medical degree from George Washington University School of Medicine, completed her neurology residency at the University of North Carolina Hospital, and became the first neurology sleep fellow at Johns Hopkins University School of Medicine in 2004.

With more than 122 scholarly works, Dr. Gamaldo is an award-winning educator and researcher with expertise in sleep medicine, medical education, and clinical care.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Charlene Gamaldo, faculty for this educational activity, has the following relevant financial relationships: Consultant: Apnimed, Cadence Health Capital, Incannex, Idorsia, Jazz, MoonBrew, Takeda, UpToDate.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.

PA Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until July 1st 2027. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

This continuing education activity is active starting October 14th 2026, and will expire on July 1st 2027.

Estimated time to complete this activity: 30 Minutes